_s-w-x-bristol-mobile-app-preview-swx797w.jpg "S W X Bristol - Mobile App Preview - SWX797W from www swx Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 1 min 94 sec
✓ Published: 21-Oct-2023
✓ Published: 21-Oct-2023
Description:
This is a preview of what a mobile ordering app designed for S W X Bristol and powered by SwiftCloud could look like. Your customised app could be live in just 16 weeks so visit www.swiftcloud.co.uk to book a demo.This video has been prepared specifically for the team at S W X Bristol and not for general marketing purposes.It will be deleted in due course but contact sales@swiftcloud.co.uk to have it deleted immediately
This is a preview of what a mobile ordering app designed for S W X Bristol and powered by SwiftCloud could look like. Your customised app could be live in just 16 weeks so visit www.swiftcloud.co.uk to book a demo.This video has been prepared specifically for the team at S W X Bristol and not for general marketing purposes.It will be deleted in due course but contact sales@swiftcloud.co.uk to have it deleted immediately
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
_review-of-the-sony-pxw-fx9-the-movie-part-1.webp "Part 1 of 2nnPart 2 here: https://vimeo.com/pbreviews/review/397858591/bb86cdde4dnn")
_review-of-the-sony-pxw-fx9-the-movie-part-2.webp "Part 2 or 2 nnPart 1 here: https://vimeo.com/pbreviews/review/397858639/850b41d8e5nn")
_how-immutep-treats-head-amp-neck-cancer.webp "While Immutep boasts development candidates that have been licenced to Novartis AG (SWX: NOVN) in the area of cancer and GlaxoSmithKline plc (GSK; LON: GSK) in the area of autoimmune diseases, as well as an internal autoimmune disease candidate, IMP761 (which is close to commencing clinical trials), the company’s primary asset is efti. Efti is in several current, and many planned, clinical trials. While it could be argued that efti is furthest down the path toward a potential approval for the")
_lonza-aktie-von-hlinka-agfif.webp "Marktbeurteilung von Lonza (Ticker LONN an der SWX). Heute bezieht sich unsere kurze Zusammenfassung auf die Schweizer Aktie: LONZA (LONN), welche an der Schweizer Börse gehandelt wird. Die Lonza Group AG ist ein schweizerisches Chemie- und Pharmaunternehmen mit Hauptsitz in Basel:www.lonza.comnnnUnsere Analyse/Research ist sehr umfangreich, hier nur eine kurze Zusammenfassung: Solide Margen, hohes defensives Wachstum, Dividende und Aktienrückkaufprogramm, gut positioniert in der Auftragspro")
_review-of-the-sony-pxw-fx9-the-movie-part-1.jpg)
_review-of-the-sony-pxw-fx9-the-movie-part-2.jpg)
_how-immutep-treats-head-amp-neck-cancer.jpg)
_lonza-aktie-von-hlinka-agfif.jpg)
![[+]](/images/menu.gif){kind=small}